Precigen, Inc. (PGEN) 8-K Summary
Business Context and Reporting Period
Precigen, Inc. filed a Form 8-K on November 13, 2025, to report its financial results for the quarter ended September 30, 2025. The company is incorporated in Virginia and trades on the Nasdaq Global Select Market under the symbol PGEN.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report serves as a notification that these results are detailed in a press release attached as Exhibit 99.1, which is not included in the provided text.
Material Changes
No material changes versus the prior comparable period are described in the filing text. The document references the attached press release for operational and financial details but does not summarize them directly.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These elements are presumed to be contained within the referenced Exhibit 99.1 press release.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated November 13, 2025) for actual revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the attached exhibit.
- Confirm if there were any changes in capital structure or financing activities during the quarter.